Sebetralstat
- Generic Name
- Sebetralstat
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26FN5O4
- CAS Number
- 1933514-13-6
- Unique Ingredient Identifier
- O5ZD2TU2B7
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
- Conditions
- Hereditary Angioedema
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Registration Number
- NCT06628713
- Locations
- 🇺🇸
KalVista Investigative Site, Scottsdale, Arizona, United States
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04349800
- Locations
- 🇬🇧
KalVista Investigative Site, Wales, United Kingdom
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04208412
- Locations
- 🇬🇧
KalVista Investigative Site, Newcastle, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath